Short answer · Medically reviewed summary · Last updated: 2026-05-08
Dysferlinopathy, which encompasses Miyoshi Myopathy, is classified under the ICD-10 code G71.09 (Other specified muscular dystrophies) and the ICD-9 code 359.1 (Hereditary progressive muscular dystrophy). Because specific coding for rare diseases can be broad, clinicians often use these codes to document the condition within electronic health records for billing and diagnostic purposes. What exactly is Dysferlinopathy and Miyoshi Myopathy? Dysferlinopathy is a group of rare, autosomal recessive muscular dystrophies caused by mutations in the DYSF gene.
ICD10 code of Dysferlinopathy - Miyoshi Myopathy and ICD9 code
ICD-10 and ICD-9 codes for Dysferlinopathy - Miyoshi Myopathy, with classification details for clinicians, coders and patients.
Dysferlinopathy, which encompasses Miyoshi Myopathy, is classified under the ICD-10 code G71.09 (Other specified muscular dystrophies) and the ICD-9 code 359.1 (Hereditary progressive muscular dystrophy). Because specific coding for rare diseases can be broad, clinicians often use these codes to document the condition within electronic health records for billing and diagnostic purposes.
What exactly is Dysferlinopathy and Miyoshi Myopathy?
Dysferlinopathy is a group of rare, autosomal recessive muscular dystrophies caused by mutations in the DYSF gene. Miyoshi Myopathy is a specific clinical presentation of Dysferlinopathy characterized primarily by the early involvement of the posterior calf muscles. At DiseaseMaps.org, 33 individuals currently share their experiences living with the challenges and clinical progression of Dysferlinopathy - Miyoshi Myopathy, providing a unique look into the patient journey.
How are these diagnostic codes used in clinical practice?
Medical coding is essential for ensuring that patients with Dysferlinopathy - Miyoshi Myopathy receive appropriate insurance coverage and specialized care. Because Dysferlinopathy represents a spectrum of phenotypes, including Limb-Girdle Muscular Dystrophy (LGMD) type R2, accurate coding helps researchers track the prevalence of these conditions globally. When your physician enters G71.09, it signals to the healthcare system that the patient requires specialized neurological management.
What are the key clinical features of this condition?
Understanding the clinical markers of Dysferlinopathy - Miyoshi Myopathy is vital for both patients and providers. Common features include:
- Onset: Typically occurs in late adolescence or early adulthood, usually between ages 15 and 25.
- Muscle Involvement: Initial weakness and atrophy often begin in the gastrocnemius and soleus muscles (the calves).
- Biomarkers: Patients typically show significantly elevated serum creatine kinase (CK) levels, often 10 to 100 times the upper limit of normal.
- Progression: Over time, weakness may progress to the proximal muscles of the thighs, hips, and shoulders.
Next steps
- Consult a neuromuscular specialist or a neurologist familiar with limb-girdle muscular dystrophies to confirm your diagnosis via genetic testing.
- Connect with the 33 community members at DiseaseMaps.org to share management strategies and emotional support.
- Reach out to organizations like the Jain Foundation, which focuses specifically on research and clinical trials for Dysferlinopathy.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.
References
- Orphanet: Dysferlinopathy (ORPHA:252)
- NIH Genetic and Rare Diseases Information Center (GARD): Dysferlinopathy
- OMIM (Online Mendelian Inheritance in Man): #254130 (Miyoshi Myopathy)
- The Jain Foundation: Resources for Dysferlinopathy patients
